{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:01:54Z","timestamp":1781726514968,"version":"3.54.5"},"reference-count":33,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The best treatment of type II mixed cryoglobulinemia (MC) has still to be defined. Antiviral treatment for the frequent underlying infectious trigger hepatitis C virus (HCV) may be ineffective, contraindicated, or not tolerated in a fraction of cases, whereas current immunosuppressive treatments may lead to relevant complications. Selective B-cell blockade with rituximab was used in this study, based on favorable results in preliminary experience. Fifteen consecutive patients with type II MC (HCV-related in 12 of 15) were treated with rituximab, 375 mg\/m2 intravenously weekly for 4 weeks. Only medium- to low-dose steroids were allowed, if already administered at the time of recruitment. All patients had active disease, poorly controlled or difficult to manage with previous treatments, including corticosteroids in all. Efficacy and safety of rituximab therapy were evaluated in the following 6 months. The overall follow-up after rituximab treatment ranged from 9 to 31 months. Rituximab proved effective on skin vasculitis manifestations (ulcers, purpura, or urticaria), subjective symptoms of peripheral neuropathy, low-grade B-cell lymphoma, arthralgias, and fever. Nephritis of recent onset went into remission in one case. Laboratory features, that is, significantly decreased serum rheumatoid factor and cryoglobulins and increased C4, were consistent with the clinical efficacy. Treatment was well tolerated, with no infectious complications. Thrombosis of retinal artery or self-limiting panniculitis occurred in one patient each. Rituximab may represent a safe and effective alternative to standard immunosuppression in type II MC. Controlled studies are needed to better define drug indications and the cost-efficacy profile in the different systemic manifestations.<\/jats:p>","DOI":"10.1182\/blood-2002-09-2856","type":"journal-article","created":{"date-parts":[[2003,5,5]],"date-time":"2003-05-05T19:24:00Z","timestamp":1052162640000},"page":"3827-3834","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":393,"title":["Efficacy and safety of rituximab in type II mixed cryoglobulinemia"],"prefix":"10.1182","volume":"101","author":[{"given":"Francesco","family":"Zaja","sequence":"first","affiliation":[{"name":"From the Divisions of Hematology-Dipartimento di Ricerche Mediche e Morfologiche and of Rheumatology-Dipartimento di Patologia e Medicina Sperimentale e Clinica, University of Udine, Italy; Department of Medicine, Hospital of Pordenone, Italy; Institute of Hematology and Medical Oncology L. A. Seragnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Vita","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology-Dipartimento di Ricerche Mediche e Morfologiche and of Rheumatology-Dipartimento di Patologia e Medicina Sperimentale e Clinica, University of Udine, Italy; Department of Medicine, Hospital of Pordenone, Italy; Institute of Hematology and Medical Oncology L. A. Seragnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Mazzaro","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology-Dipartimento di Ricerche Mediche e Morfologiche and of Rheumatology-Dipartimento di Patologia e Medicina Sperimentale e Clinica, University of Udine, Italy; Department of Medicine, Hospital of Pordenone, Italy; Institute of Hematology and Medical Oncology L. A. Seragnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Sacco","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology-Dipartimento di Ricerche Mediche e Morfologiche and of Rheumatology-Dipartimento di Patologia e Medicina Sperimentale e Clinica, University of Udine, Italy; Department of Medicine, Hospital of Pordenone, Italy; Institute of Hematology and Medical Oncology L. A. Seragnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Damiani","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology-Dipartimento di Ricerche Mediche e Morfologiche and of Rheumatology-Dipartimento di Patologia e Medicina Sperimentale e Clinica, University of Udine, Italy; Department of Medicine, Hospital of Pordenone, Italy; Institute of Hematology and Medical Oncology L. A. Seragnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"De Marchi","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology-Dipartimento di Ricerche Mediche e Morfologiche and of Rheumatology-Dipartimento di Patologia e Medicina Sperimentale e Clinica, University of Udine, Italy; Department of Medicine, Hospital of Pordenone, Italy; Institute of Hematology and Medical Oncology L. A. Seragnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Michelutti","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology-Dipartimento di Ricerche Mediche e Morfologiche and of Rheumatology-Dipartimento di Patologia e Medicina Sperimentale e Clinica, University of Udine, Italy; Department of Medicine, Hospital of Pordenone, Italy; Institute of Hematology and Medical Oncology L. A. Seragnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology-Dipartimento di Ricerche Mediche e Morfologiche and of Rheumatology-Dipartimento di Patologia e Medicina Sperimentale e Clinica, University of Udine, Italy; Department of Medicine, Hospital of Pordenone, Italy; Institute of Hematology and Medical Oncology L. A. Seragnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology-Dipartimento di Ricerche Mediche e Morfologiche and of Rheumatology-Dipartimento di Patologia e Medicina Sperimentale e Clinica, University of Udine, Italy; Department of Medicine, Hospital of Pordenone, Italy; Institute of Hematology and Medical Oncology L. A. Seragnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Ferraccioli","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology-Dipartimento di Ricerche Mediche e Morfologiche and of Rheumatology-Dipartimento di Patologia e Medicina Sperimentale e Clinica, University of Udine, Italy; Department of Medicine, Hospital of Pordenone, Italy; Institute of Hematology and Medical Oncology L. A. Seragnoli, University of Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111703145055700_B1","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0889-8588(05)70129-5","article-title":"Cryoglobulinaemia.","volume":"13","author":"Dispenzieri","year":"1999","journal-title":"Hematol Oncol Clin North America."},{"key":"2019111703145055700_B2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/1529-0131(200001)43:1<94::AID-ANR12>3.0.CO;2-8","article-title":"Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia.","volume":"43","author":"De Vita","year":"2000","journal-title":"Arthritis Rheum."},{"key":"2019111703145055700_B3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1056\/NEJM199403173301104","article-title":"Interferon alpha 2a therapy in cryoglobulinemia associated with hepatitis C virus.","volume":"330","author":"Misiani","year":"1994","journal-title":"N Engl J Med."},{"key":"2019111703145055700_B4","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1182\/blood.V84.10.3336.3336","article-title":"Natural interferon alpha versus its combination with 6-metil-prednisolone in the therapy of type II mixed cryoglobulinemia: a long term, randomized, controlled study.","volume":"84","author":"Dammacco","year":"1994","journal-title":"Blood."},{"key":"2019111703145055700_B5","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood.V90.10.3865","article-title":"Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection.","volume":"90","author":"Casato","year":"1997","journal-title":"Blood."},{"key":"2019111703145055700_B6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00002281-200201000-00006","article-title":"Cryoglobulinemia vasculitis.","volume":"14","author":"Coca","year":"2002","journal-title":"Curr Opin Rheumatol."},{"key":"2019111703145055700_B7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1046\/j.1365-2036.1999.00581.x","article-title":"Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.","volume":"13","author":"Calleja","year":"1999","journal-title":"Aliment Pharmacol Ther."},{"key":"2019111703145055700_B8","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.V92.8.2983","article-title":"Interferon alpha and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia [letter].","volume":"92","author":"Donada","year":"1998","journal-title":"Blood."},{"key":"2019111703145055700_B9","first-page":"1641","article-title":"Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection.","volume":"22","author":"La Civita","year":"1996","journal-title":"J Rheumatol."},{"key":"2019111703145055700_B10","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/1529-0131(199905)42:5<1051::AID-ANR26>3.0.CO;2-Q","article-title":"Interferon-alpha may exacerbate cryoglobulinemia-related ischemic manifestations.","volume":"42","author":"Cid","year":"1999","journal-title":"Arthritis Rheum."},{"key":"2019111703145055700_B11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/ki.1995.78","article-title":"Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis.","volume":"47","author":"Tarantino","year":"1995","journal-title":"Kidney Int."},{"key":"2019111703145055700_B12","first-page":"S191","article-title":"Guidelines for the management of essential mixed cryoglobulinemia.","volume":"13(suppl 13)","author":"Tavoni","year":"1995","journal-title":"Clin Exp Rheumatol."},{"key":"2019111703145055700_B13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0889-857X(05)70143-5","article-title":"Update on cyclophosphamide for systemic lupus erythematosus.","volume":"26","author":"Ortmann","year":"2000","journal-title":"Rheum Dis Clin North Am."},{"key":"2019111703145055700_B14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20.","volume":"83","author":"Reff","year":"1994","journal-title":"Blood."},{"key":"2019111703145055700_B15","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-CD28 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood."},{"key":"2019111703145055700_B16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/sonc.2002.30145","article-title":"Rituximab: ongoing and future clinical development.","volume":"29","author":"Grillo-Lopez","year":"2002","journal-title":"Semin Oncol."},{"key":"2019111703145055700_B17","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.10476","article-title":"B cell-ablative therapy for the treatment of autoimmune diseases.","volume":"46","author":"Patel","year":"2002","journal-title":"Arthritis Rheum."},{"key":"2019111703145055700_B18","first-page":"1157","article-title":"Rituximab for the treatment of type II mixed cryoglobulinemia [letter].","volume":"84","author":"Zaja","year":"1999","journal-title":"Haematologica."},{"key":"2019111703145055700_B19","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","article-title":"Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.","volume":"46","author":"De Vita","year":"2002","journal-title":"Arthritis Rheum."},{"key":"2019111703145055700_B20","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/art.10345","article-title":"Rituximab for the treatment of type II mixed cryoglobulinemia [letter].","volume":"46","author":"Zaja","year":"2002","journal-title":"Arthritis Rheum."},{"key":"2019111703145055700_B21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1182\/blood.V90.2.776","article-title":"Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection.","volume":"90","author":"De Vita","year":"1997","journal-title":"Blood."},{"key":"2019111703145055700_B22","volume-title":"aids to the examination of the peripheral nervous system. Memorandum no. 45.","author":"Medical Research Council","year":"1981"},{"key":"2019111703145055700_B23","first-page":"1346","article-title":"Electrophysiologic testing and laboratory aids in the diagnosis of neuromuscular disease.","volume-title":"Adams and Victor's Principles of Neurology. 7th ed.","author":"Victor","year":"2001"},{"key":"2019111703145055700_B24","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.4049\/jimmunol.167.8.4710","article-title":"T cell activation in rheumatoid synovium is B cell dependent.","volume":"167","author":"Takemura","year":"2001","journal-title":"J Immunol."},{"key":"2019111703145055700_B25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1212\/WNL.32.7.725","article-title":"Pathogenesis of cryoglobulinemic neuropathy.","volume":"32","author":"Chad","year":"1982","journal-title":"Neurology."},{"key":"2019111703145055700_B26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s004280050380","article-title":"Hepatitis C virus infection of peripheral nerves in type II cryoglobulinemia.","volume":"434","author":"Bonetti","year":"1999","journal-title":"Virchows Arch."},{"key":"2019111703145055700_B27","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V100.5.1765.h81702001765_1765_1773","article-title":"Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects.","volume":"100","author":"Rose","year":"2002","journal-title":"Blood."},{"key":"2019111703145055700_B28","first-page":"79","article-title":"The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.","volume":"27(suppl 12)","author":"Treon","year":"2000","journal-title":"Semin Oncol."},{"key":"2019111703145055700_B29","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1182\/blood.V91.7.2433","article-title":"Somatic hypermutation, clonal diversity, and preferential expression of the VH51p1\/VLkv325 immunoglobulin gene combination in hepatitis C virus associated immunocytomas.","volume":"7","author":"Ivanovski","year":"1998","journal-title":"Blood."},{"key":"2019111703145055700_B30","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood.V96.10.3578","article-title":"Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia.","volume":"96","author":"De Re","year":"2000","journal-title":"Blood."},{"key":"2019111703145055700_B31","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood.V98.13.3745","article-title":"The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis.","volume":"98","author":"Quinn","year":"2001","journal-title":"Blood."},{"key":"2019111703145055700_B32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1172\/JCI115007","article-title":"New roles for rheumatoid factor.","volume":"87","author":"Carson","year":"1991","journal-title":"J Clin Invest."},{"key":"2019111703145055700_B33","first-page":"11","article-title":"Hepatitis C virus and mixed cryoglobulinemia: recent developments and perspectives for research [abstract].","volume":"87(suppl 1-9)","author":"De Vita","year":"2002","journal-title":"Haematologica."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/10\/3827\/1259352\/h81003003827.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/10\/3827\/1259352\/h81003003827.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:15:03Z","timestamp":1573978503000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/10\/3827\/19150\/Efficacy-and-safety-of-rituximab-in-type-II-mixed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,15]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,5,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-09-2856","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5,15]]}}}